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Protective effects of an aptamer inhibitor of neutrophil elastase
in lung inflammatory injury 
Nicolas M. Bless*, Drew Smith†, Josephine Charlton†, Boris J. Czermak*,
Hagen Schmal*, Hans P. Friedl* and Peter A. Ward‡
Neutrophils play an important part in the development of
acute inflammatory injury. Human neutrophils contain
high levels of the serine protease elastase, which is
stored in azurophilic granules and is secreted in
response to inflammatory stimuli. Elastase is capable of
degrading many components of extracellular matrix [1–4]
and has cytotoxic effects on endothelial cells [5–7] and
airway epithelial cells. Three types of endogenous
protease inhibitors control the activity of neutrophil
elastase, including a-1 protease inhibitor (a−1PI), 
a-2 macroglobulin and secreted leukoproteinase
inhibitor (SLPI) [8–10]. A disturbed balance between
neutrophil elastase and these inhibitors has been found
in various acute clinical conditions (such as adult
respiratory syndrome and ischemia-reperfusion injury)
and in chronic diseases. We investigated the effect of
NX21909, a selected oligonucleotide (aptamer) inhibitor
of elastase, in an animal model of acute lung
inflammatory disease [11–14]. This inhibitor was
previously selected from a hybrid library of randomized
DNA and a small-molecule irreversible inhibitor of
elastase (a valine diphenyl ester phosphonate, Figure 1),
by the blended SELEX process [15]. We show that
NX21909 inhibits lung injury and neutrophil influx in a
dose-dependent manner, the first demonstration of
efficacy by an aptamer in an animal disease model. 
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Results and discussion 
Intrapulmonary deposition of IgG immune complexes into
rat lung results in intense, acute inflammatory injury that
is dependent on release from recruited neutrophils and
tissue macrophages of toxic oxygen products and proteases.
These processes disrupt the structural barriers established
by the extracellular matrix [16,17], resulting in lung leak
and hemorrhage. Intrapulmonary immune complexes are
formed by intratracheal instillation of anti-bovine serum
albumin (BSA) IgG followed by intravenous adminis-
tration of BSA. The IgG immune complex model of lung
injury is triggered by immune complexes that have been
shown by immunostaining techniques to be deposited
along alveolar walls of the lung [18]. Using this system, we
tested the ability of an aptamer inhibitor of elastase to
inhibit lung leak and neutrophil influx. 
We recently described the isolation and characterization of
highly potent and specific inhibitors of neutrophil elastase
by the process of blended SELEX [15,19]. For this, a small
molecule (a valyl diphenylester phosphonate) was incorpo-
rated into a large library of nucleic acid sequences (>1012).
The library was iteratively selected for the sequences that
best promote the covalent reaction of the small molecule
with elastase, and these sequences were amplified to initi-
ate another round of selection. The most active inhibitors
isolated by this process show inactivation rate constants
greater than 108 M–1 min–1 for human neutrophil elastase.
This rate is 104-fold greater than that for the phosphonate
alone and is currently the fastest inactivation rate constant
reported for any synthetic irreversible inhibitor of elastase. 
Figure 1
Structure of the elastase inhibitor NX21909. This is composed of two
DNA oligonucleotides annealed together, shown folded into the
proposed secondary structure. Upper-case letters in the top strand
indicate nucleotides that were randomized in the starting library. The
bottom strand is the ‘splint’ oligo, which was annealed to the fixed-
sequence regions of the library. The active-site serine of elastase
attacks the phosphorus atom, displacing a phenyl group to form a
stable serine-phosphonate ester.
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The compound used for the current studies, termed
NX21909, is shown in Figure 1. NX21909 inhibits rat elas-
tase at concentrations greater than 20 nM, but no inhibi-
tion of cathepsin G activity was observed at inhibitor
concentrations of up to 100 nM (Figure 2). Cathepsin G is
a serine protease that is also released by activated neu-
trophils and is particularly abundant in rat neutrophils
[16]. We calculate the second-order rate constants for inac-
tivation as 1.1 ± 0.2 × 107 M–1 min–1 for rat elastase and less
than 104 M–1 min–1 for rat cathepsin G. These inactivation
rates mirror the specificity displayed for the human forms of
elastase and cathepsin G and indicate that NX21909 can be
used as a specific probe for the effects of elastase in
disease models. 
IgG immune complex-induced lung injury was quantified
at 4 h by changes in vascular permeability as measured by
leakage of [125I]BSA into lung parenchyma (Figure 3a). Per-
meability is a relatively sensitive indicator of lung injury,
indicating a break in the lung vascular barrier, as this tech-
nique measures the extravascular presence of [125I]albumin
in lungs whose vasculature has been flushed to remove
[125I]albumin present in the blood. In the IgG model, mean
permeability values (the ratio of radioactivity in the lungs to
that in the blood) in the negative and positive controls were
0.15 ± 0.02 and 0.54 ± 0.03, respectively. When 5–40 nmol
of the inhibitor complex were instilled intratracheally, the
permeability index fell in proportion to the dose (Figure
3c). At the highest dose, permeability was reduced by 38%
(permeability = 0.39, P = 0.003 compared to the positive
control, Figure 3a). The reduction of permeability caused
by 40 nmol NX21909 compares to 54% reduction when
200 nmol recombinant human SLPI, a serine protease
inhibitor, was used in the same model of lung injury [16]. 
We controlled for nonspecific effects of oligonucleotide
administration by testing each subunit of the inhibitor
separately. The intratracheal administration of 20 nmol of
the small splint oligo subunit of the inhibitor (Figure 1)
did not result in a significant reduction in the permeability
index (Figure 3a). This subunit is able to inactivate
human and rat neutrophil elastase in vitro, albeit slowly,
with an inactivation rate constant 104–105 M–1 min–1 (data
not shown). Evidently, this level of activity is insufficient
to have a biological effect at the concentrations used. Sim-
ilarly, intratracheal administration of 20 nmol of the large
42-mer DNA subunit of the inhibitor also failed to signifi-
cantly reduce permeability ( Figure 3a). This subunit does
not inhibit elastase in vitro. 
The recruitment of neutrophils into rat lungs injured by
IgG immune complex was quantified by measurement of
lung myeloperoxidase (MPO) content. MPO reliably mea-
sures all neutrophils in the lung (exclusive of nonadherent
neutrophils in blood that have been flushed from the
lungs). Because of the neutrophil dependency of injury
caused by intrapulmonary deposition of immune com-
plexes, a close correlation exists between MPO content
and extent of lung injury [18]. 
Positive (0 nmol) controls showed a 91 (± 7)% increase in
MPO content over negative (sham) controls (Figure 3b).
Intratracheal administration at time 0 of 5–40 nmol of the
neutrophil elastase inhibitor resulted in a dose-dependent
decrease in MPO content, with a reduction of 53 (± 10)%
at the 40 nmol dose. This amount of inhibition of MPO
content by NX21909 compares to 37% reduction with
200 nmol SLPI in the same model of lung injury [16]. The
intratracheal administration of 20 nmol of the small splint
oligo subunit of the inhibitor did not result in significant
change in MPO content compared to the value in the posi-
tive controls, which were otherwise untreated (Figure 3b).
The large subunit also failed to cause significant reduc-
tions (<5%) in MPO content (Figure 3b). 
Regression analysis shows that the reductions in vascular
leak and neutrophil influx are strongly dose dependent
(Figure 3c). The dependence appears to be linear in the
range of doses used. This simple linearity is consistent
with a model in which the biological effects of NX21909
are mediated by stoichiometric neutralization of elastase.
An alternative hypothesis is that the inhibitor affects the
ability of IgG to induce an inflammatory reaction. This
sort of nonspecific interaction of the nucleic acids with
IgG seems unlikely, however, as neither individual subunit
is able to attenuate the immune response. 
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Figure 2
Inhibition of rat neutrophil proteases. Assays for rat neutrophil elastase
(rNE) and rat cathepsin G (rCG) are described in Materials and
methods. k inact obs is the fraction of enzyme inactivated per minute.
Theoretical curves are linear regression by least-squares analysis. The
slopes of these curves are the observed second-order rate constants
for inactivation. 
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Neutrophil elastase appears to play an important part in
numerous inflammatory conditions of the lung. The devel-
opment of neutrophil elastase inhibitors for therapeutic
purposes has been pursued using a variety of strategies,
including the identification and production of endoge-
nous inhibitors (such as α-1PI and SLPI) as well as syn-
thesis of smaller organic molecules with anti-elastase activ-
ity. Serine proteases form a transient covalent complex
between the enzyme active-site serine and the substrate
peptide acyl carbon. Irreversible inhibitors, such as the
valyl phosphonate moiety of NX21909 (Figure 1), form a
stable version of this complex, thereby inactivating the
enzyme [20]. 
The aptamer inhibitor of elastase, NX21909, has similar
inhibitory effects on vascular leak and neutrophil infiltra-
tion, strengthening the hypothesis that elastase has a key
role in the development of lung injury in inflammatory
diseases. Elastase inhibitors may reduce lung injury
directly, by blocking the degradation of connective tissue
by elastase or, more indirectly, by blocking the recruit-
ment of neutrophils to the site of inflammation. The latter
mechanism may be of particular importance in the devel-
opment of therapeutic agents, as activated neutrophils
release a number of degradative enzymes, oxygen metabo-
lites and cytokines. These factors may cause more damage
than could be attributed to the enzymatic activity of 
elastase alone. 
Aptamers are a relatively new drug discovery platform that
exploits the ability of nucleic acids to fold into stable
structures that bind with high affinity and specificity to a
variety of target molecules [21,22]. In the case of anti-elas-
tase aptamers, we have now shown that we can obtain
extremely fast irreversible inhibitors of elastase [15,19]
and that these inhibitors are effective in ex vivo [19] and,
in the present study, in vivo animal models of inflamma-
tory disease. These results show continued progress in the
development of aptamer technology, and in the develop-
ment of anti-inflammatory therapeutics. 
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Figure 3
Protective effects of elastase inhibitors in lung injury. In animals
undergoing IgG immune complex-induced lung injury, anti-BSA IgG
was instilled into rat lungs with no inhibitor, or the individual
components of the inhibitor at 20 nmol, or the complete inhibitor at
5–40 nmol. Sham controls were performed with saline alone.
Numbers of replicate experiments are indicated above each column;
bars = 1 s.e.m. *= P < 0.05; ** = P < 0.01. (a) Effect on vascular
leak. The permeability index is computed as the quotient of c.p.m.
[125I]BSA per gram of lung tissue divided by c.p.m. per ml blood. (b)
Effect on neutrophil influx. Whole lung MPO was measured, and
normalized to the positive control (0 nmol) value, defined as 100. (c)
Dose dependence of effects on vascular leak and neutrophil influx.
Data from (a) and (b) are replotted as percent reduction, which is
calculated as 100 × (P – X)/(P – N) where P is the positive control
(0 nmol) value, X is the value for a given dose, and N is the negative
control (sham) value. Theoretical lines are from linear regressions.
For vascular leak, R = 0.96 (P = 0.009); for neutrophil influx, R =
0.96 (P = 0.008).
Materials and methods 
IgG immune complex-induced alveolitis 
Male Long Evans (specific pathogen-free) rats (275–300 g, Charles
River Breeding Laboratories, Inc.) were used for all studies. Intraperi-
toneal injections of ketamine (12.5–15.0 mg per 100 g body weight)
were used for sedation and anesthesia. Polyclonal rabbit IgG containing
2.5 mg anti-BSA (Organon Technique Corp.) was instilled [in a volume of
300 µl phosphate-buffered saline (PBS)] into the lungs via a tracheal
cannula. BSA (10 mg) was injected intravenously (i.v.) immediately there-
after (in a volume of 0.5 ml PBS). The rats were killed 4 h later. 
Elastase inhibitor
The elastase inhibitor NX21909 is a 42-nucleotide derivative of the 71-
nucleotide isolate ED38, described in [15]. The structure of the inhibitor
is shown schematically in Figure 1. DNA for the larger subunit was syn-
thesized by Operon, and purified by reverse-phase HPLC. The smaller
subunit, containing the valyl phosphonate, was synthesized and purified
as described [15]. The intact inhibitor was assembled by annealing the
two constituent oligonucleotides in a 1:1 molar ratio at 65°C for 2 min,
then cooling to 37°C. Inhibition of rat neutrophil elastase and cathepsin
G (partially purified, Athens Research) was measured by a colorimetric
assay, and analyzed by a progress curve method [19]. The substrate for
elastase was N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide, and the
cathepsin G substrate was N-methoxysuccinyl-Ala-Ala-Pro-Phe-p-nitro-
anilide (Calbiochem), both at 0.5 mM. 
Intrapulmonary use of the neutrophil elastase inhibitor 
The elastase inhibitor was instilled intratracheally together with the poly-
clonal rabbit anti-BSA IgG. The neutrophil elastase inhibitor was used in
total amounts ranging from 5–40 nmol. Both the elastase inhibitor and
polyclonal rabbit IgG were dissolved in a volume of 150µl PBS, pH 7.4. 
Measurement of lung permeability 
Trace amounts of [125I]BSA (5 µCi, approx. 1 µg BSA) were mixed
with 10 mg BSA and injected i.v. in order to have a quantitative marker
of the extent of lung injury. After 4 h the rats were killed and 1.0 ml
blood was obtained from the inferior vena cava. The pulmonary artery
was flushed with 10 ml PBS. The amounts of radioactivity ([125I]BSA)
in the blood sample and that remaining in the perfused lung were quan-
titated on a scintillation counter. Negative control animals received
[125I]BSA intravenously and 2.5 mg nonspecific rabbit IgG (instead of
the polyclonal anti-BSA) intratracheally. 
Measurement of neutrophil accumulation by myeloperoxidase
quantification 
Whole lungs obtained at the time of killing were flushed via the 
pulmonary artery with 10 ml PBS, dissected, and frozen immediately in
liquid nitrogen. After mechanical homogenization, MPO content was
quantitated using a protocol described in [23]. 
Statistical analysis
All values were expressed as mean ± 1.0 s.e.m. Data sets were exam-
ined with one- and two-way ANOVA and individual group means were
then compared by Student’s t-test. 
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